Zainab Obaidi, MD
Nephrology · Baltimore, MDNPI 1891102505
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 53.4% of the total. 2025 is the largest year on record at $23,213, more than ten times the $118 reported in 2022. Among nephrology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $453.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$21K
- Travere Therapeutics, Inc.$12K
- Amgen$5K
- AstraZeneca$297
- Aurinia Pharma U.S., Inc.$246
- Novartis$232
- plus $594 from 6 others
What the payments were for
- Consulting fees$10,20026%
- Speaking & faculty fees$18,14847%
- Travel & lodging$5,95815%
- Food & beverage$4,58412%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 27 | $20,843 |
| Travere Therapeutics, Inc. | 34 | $12,065 |
| Amgen | 10 | $4,746 |
| AstraZeneca | 3 | $297 |
| Aurinia Pharma U.S., Inc. | 2 | $246 |
| Novartis | 3 | $232 |
| Bayer | 1 | $158 |
| Apellis Pharmaceuticals, Inc. | 2 | $154 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $121 |
| GSK | 1 | $116 |
| Novo Nordisk | 1 | $32 |
| Genentech, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,023 in reported general payments places this provider in the 95th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $25,219 |
| FarxigaDapagliflozin Propanediol | 29 | $24,500 |
| KerendiaFinerenone | 14 | $16,817 |
| OzempicSemaglutide | 13 | $11,205 |
| Nifedipine ErNifedipine | 20 | $467 |
| Calcitriol | 21 | $363 |
| Tamsulosin Hcl | 15 | $341 |
| Losartan Potassium | 22 | $335 |
| Lisinopril | 29 | $187 |
| Prednisone | 14 | $171 |
| Furosemide | 26 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $297 | $24,50029 claims |
| BayerKerendia | $158 | $16,81714 claims |
| Novo NordiskOzempic | $32 | $11,20513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 nephrology providers in Maryland.
Other nephrology in Baltimore
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
- Christopher SperatiBaltimore$37K
- Charlotte Jones BurtonBaltimore$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.